If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Product Launch » Resource Allocation
Download FREE Excerpt
9 Info Graphics
20 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Pharmaceutical companies make significant investments in the development and launch of new oncology products. Consequently, companies often pursue a second indication for the same oncology product in order to not only expand a product's patient base but also to leverage savings on launch spending by using infrastructure and resources from the first indication launch.
But how much can a company expect to save from a first launch in an oncology portfolio to a second indication launch - and across what activities and staff? This benchmark study will help marketing and brand leaders better understand the leverage and synergy points for later launches in an oncology portfolio.
The study includes investment benchmarks across pre-launch, launch and post-launch periods for first indication oncology launches and second indication launches. It also compares staffing and activity spending across the first and second launches and examines areas where launch leaders can expect to leverage the most savings.
This analysis probes Oncology product staffing levels for 12 companies and 20 U.S. project launches. Executives at the VP level, Functional Heads, Senior Directors and Directors were among the participants who informed this study.